Table 1.
Basic characteristics of included studies in this study
| Included studies | Country | Study design | Sample size (E/C) | Year (E/C) | RLRL brand/wavelength (nm) | Control group | Follow-up time (m) | Outcome measures |
|---|---|---|---|---|---|---|---|---|
| Yu Jiang, 2019 | China | RCT | 117/129 | 8–13/8.1–13 | Eyerising/650 | Single-vision spectacle | 12 | AL, SE |
| Lei Tian, 2021 | China | RCT | 91/88 | 9.49±1.59/9.66±1.65 | Myopia and amblyopia treatment apparatus/650 | Single-vision spectacle | 6 | AL, SE |
| Yanxian Chen, 2020 | China | RCT | 29/28 | 9.78±1.58/10.31±1.90 | Eyerising/650 | 0.01% Atropine eye drops | 12 | AL, SE |
| Jing Dong, 2019 | China | RCT | 56/55 | 10.3±2.07/9.86±1.41 | Eyerising/650 | The sham device | 6 | AL, SE |
| Yi Yan, 2019 | China | RCT | 70/70 | 8–12/8–12 | Eyerising/650 | Single-vision spectacle | 12 | AL, SE |
| Shiyu Jia, 2022 | China | RCT | 30/30 | 7–15/7–15 | -/650 | Single-vision spectacle | 6 | AL, SE |
AL=axial length, RCT=randomized controlled trial, SE=spherical equivalent, E/C=experimental group / control group, m=months